Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells

Autor: William R. Strohl, Michael Naso

Publikováno v: Antibodies, Vol 8, Iss 3, p 41 (2019)

The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming into age. Two TRBAs and two CAR-T cell products have been approved by

Externí odkaz: https://doaj.org/article/24215a44281d460cbabbd80abe9e86a8

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Autor: Strohl WR; BiStro Biotech Consulting, LLC, 1086 Tullo Farm Rd., Bridgewater, NJ 08807, USA. wrstrohl@gmail.com., Naso M; Century Therapeutics, 3675 Market St., Philadelphia, PA 19104, USA.

Publikováno v: Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2019 Jul 03; Vol. 8 (3). Date of Electronic Publication: 2019 Jul 03.